Kite (Gilead) Enters Strategic Collaboration and Equity Investment in Arcellx to Co-develop and Co-commercialise CART-ddBCMA

Gilead Sciences To Acquire Arcellx for $7.8 Billion to Strengthen CAR T-Cell Portfolio

February 21, 2026

Biotechnology

Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.

Kite (a Gilead Company) to Acquire Interius BioTherapeutics

August 21, 2025

Biotechnology

Kite, a Gilead company, entered into a definitive agreement to acquire Interius BioTherapeutics for $350 million in cash. The acquisition is intended to advance Kite’s in vivo CAR T-cell therapy platform by incorporating Interius’s integrating in vivo platform, delivered via a single intravenous infusion.

PAI Partners and KIRKBI A/S Acquire Armacell from Blackstone

December 4, 2019

Manufacturing

PAI Partners and KIRKBI A/S have agreed to acquire Armacell from private equity funds managed by Blackstone, with PAI becoming the majority shareholder and KIRKBI increasing its stake to a significant minority. Armacell is a Luxembourg-headquartered manufacturer of flexible and engineered foams with 24 manufacturing facilities and over 3,000 employees; CEO Patrick Mathieu will remain in place. Terms are confidential and subject to regulatory approvals, and the buyers plan to support Armacell's growth, product innovation and global expansion.

AstraZeneca to Acquire Gracell Biotechnologies (FasTCAR CAR-T) for Up to $1.2 Billion

December 27, 2023

Healthcare Services

AstraZeneca entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharmaceutical company focused on autologous cell therapies for cancer and autoimmune diseases. The deal is expected to close in the first quarter of 2024 and includes Gracell’s FasTCAR-enabled dual-targeting CAR-T therapy GC012F, with an upfront value of about $1.0 billion and total transaction value of up to about $1.2 billion including a contingent value right tied to a regulatory milestone.

Thomas H. Lee Partners Leads $100M Series D Investment in FourKites

March 24, 2021

Transportation

Thomas H. Lee Partners (THL) led a $100 million Series D growth round in FourKites, a Chicago-based real-time supply chain visibility software provider. Strategic investors Zebra Technologies, Volvo Group Venture Capital and Qualcomm Ventures joined the financing to help FourKites accelerate product innovation, expand market penetration and pursue organic and inorganic growth initiatives.

kdc/one Acquires Aerofil Technology; KKR Makes Strategic Investment in kdc/one

March 30, 2022

Manufacturing

Knowlton Development Corporation (kdc/one) acquired Aerofil Technology, a Sullivan, Missouri-based aerosol and liquid contract packager, adding North American aerosol filling capabilities to its network. Simultaneously, global investment firm KKR made a strategic minority investment in kdc/one to support the company's continued growth alongside existing investor Cornell Capital.